ICYMI, this week we had articles about a proposed ban of formaldehyde in hair relaxers, TAK-279 for psoriatic arthritis, and updated atopic dermatitis guidelines from AAD.
Study results were presented at the 2023 American Society for Dermatologic Surgery Annual Meeting in Chicago, Illinois.
In this episode, discover and learn how to address the unique challenges faced by college students diagnosed with atopic dermatitis—especially as they navigate new lifestyles and medication management.
Combined with routine treatments for vitiligo, certain CPMs proved efficacious in patients with vitiligo, with few adverse effects.
Christopher Bunick, MD, PhD, and David Light, CEO of Valisure, weigh in on the proposed formaldehyde ban.
Study authors urge clinicians to screen adult patients with AD for cognitive dysfunction.
Incorporating vitamin D may mitigate adverse effects of corticosteroids, though more research is needed to discover the best methods for topical administration in vitiligo.
Click here to answer this week's NP & PA poll.
Understanding the needs of gender-diverse patients and patients receiving gender-affirming hormones is crucial to equitable care and properly addressing patients' needs.
Investigators report 12 weeks of treatment provided a strong foundation for further evaluation of TAK-279 across the psoriatic arthritis disease spectrum.
HADLIMA is currently indicated for psoriatic arthritis, plaque psoriasis, and hidradenitis suppurativa, among others.
New technologies such as the 1726-nm laser and pneumatic assisted broad band light are emerging treatments in acne.
Vilobelimab has received Fast Track and Orphan Drug designations from the FDA, as well as an Orphan Drug designation from the European Medicines Agency for the treatment of PG.
Despite how widely used these acids often are, there is still a lack of general consensus for which are the most effective in patients with acne-prone skin.
In this week’s Pointers With Portela, the 208SkinDoc discusses the best retinol alternatives in 2023.
New lifestyle transitions can affect a patient's treatment adherence and support network. How would you help this new college student?
Kwatra discussed his research team’s findings published in JAMA Dermatology.
The guidelines update AAD’s 2014 recommendations for the management of AD with phototherapy and systemic therapies.
Catch up on the best highlights from Fall Clinical for PAs & NPs, SDPA Summer, and Maui Derm NP + PA Summer.
The case of a 45-year-old woman with AD challenges clinicians on how to consider stress as an exacerbating factor in a treatment-resistant case.
New treatments and clinical insights will be shared at this year's American College of Allergy, Asthma and Immunology Annual Scientific Meeting.
Click here to answer this week's poll for hyperhidrosis awareness month.
Data from Novartis will be presented at the 2023 American College of Allergy, Asthma, and Immunology Scientific Meeting.
Investigators noted that patients with mild psoriasis experience a less favorable status when compared to patients with moderate psoriasis.
Susan C. Taylor, MD, FAAD, and George Han, MD, PhD, share insights on vitiligo awareness, demographics, treatment approaches, and the impact of the condition on patients’ quality of life.
Grants allow investigators to uncover the potential causes and key aspects of rosacea to pave the way for improved treatment, prevention, and possibly a cure.
A new study presented at this year’s American College of Allergy, Asthma and Immunology Annual Scientific Meeting highlights the need for mental health support in patients with atopic dermatitis.
Program Chair Jay A. Lieberman, MD, provides a glimpse into the clinical pearls and dermatological educational opportunities presented at the ACAAI 2023 Annual Scientific Meeting.
Catch up on the best highlights from Maui Derm NP + PA Fall, Inflammatory Disease Summit, and SDPA Fall.
Shawn Kwatra, MD, shares his thoughts on the positive phase 3 data of OLYMPIA 2.
To stay up-to-date with the latest dermatology news, sign up to receive our eNewsletters.